| scholarly article | Q13442814 |
| P50 | author | Torsten Haferlach | Q66370751 |
| Tamara Alpermann | Q66370761 | ||
| Ulrike Bacher | Q66370775 | ||
| Claudia Haferlach | Q66370782 | ||
| Susanne Schnittger | Q66370791 | ||
| P2093 | author name string | Wolfgang Kern | |
| P2860 | cites work | Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations | Q27824843 |
| Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype | Q27824844 | ||
| Implications of NRAS mutations in AML: a study of 2502 patients | Q27824859 | ||
| Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). | Q27824861 | ||
| Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients | Q27851417 | ||
| Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. | Q27851476 | ||
| Erythroleukaemia in the north of England: a population based study | Q28209576 | ||
| Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution | Q28258018 | ||
| Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification | Q28269007 | ||
| Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease | Q28282623 | ||
| Acute erythroid neoplastic proliferations. A biological study based on 62 patients. | Q34522729 | ||
| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
| Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease | Q34524219 | ||
| Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. | Q43102402 | ||
| Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. | Q43695451 | ||
| Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia | Q44323299 | ||
| Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). | Q44373728 | ||
| Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification | Q46328691 | ||
| Erythroleukaemia and RAEB-t: a same disease? | Q53643606 | ||
| Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. | Q54655693 | ||
| Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. | Q55035685 | ||
| Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival | Q67850007 | ||
| Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML | Q73769144 | ||
| P433 | issue | 9 | |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| P304 | page(s) | 1284-1292 | |
| P577 | publication date | 2011-05-23 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells | |
| P478 | volume | 96 |
| Q48102562 | A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. |
| Q26851821 | Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities |
| Q44590610 | Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics |
| Q39575152 | Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts |
| Q48163030 | Acute leukaemia with a pure erythroid phenotype: under-recognized morphological and cytogenetic signatures associated universally with primary refractory disease and a dismal clinical outcome. |
| Q36109515 | Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. |
| Q43191865 | Acute myeloid leukemia with expanded erythropoiesis |
| Q41336647 | An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification |
| Q44219414 | Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia |
| Q50071597 | De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity |
| Q64124160 | Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia |
| Q38827726 | Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes |
| Q47719432 | Erythroleukemia-historical perspectives and recent advances in diagnosis and management |
| Q92688318 | High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia |
| Q38327599 | How unique is pure erythroid leukaemia? A retrospective analysis of seven cases and review of the literature |
| Q53412376 | Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. |
| Q41465409 | Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response |
| Q57801681 | Prognostic role of DOK family adapters in acute myeloid leukemia |
| Q92979398 | Prognostic role of SCAMP family in acute myeloid leukemia |
| Q92826014 | Prognostic value of the FUT family in acute myeloid leukemia |
| Q38779206 | Pure erythroid leukemia |
| Q36579076 | Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics |
| Q36279945 | The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification |
| Q91713562 | Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia |
Search more.